ACTL6A and cancer: Additionally, studies using xenograft mouse models have shown that treatment with histone deacetylase (HDAC) inhibitors can counteract the effects of ACTL6A overexpression on the repair of cisplatin-induced DNA damage repair, ultimately sensitizing cancer cells to cisplatin.111 These findings highlight a novel role for ACTL6A in platinum resistance and suggest a potential strategy for utilizing HDAC inhibitors in treating platinum-resistant tumors.